The concept Frederic describes of not treating the result of inflammation, rather the cause is next level. We have reason to be optimistic in LAG-3’s role in inflammation with GSK continuing development of IMP731. IMP761 could be an incredibly important medicine for patients, and blockbuster for shareholders. The Immutep pipeline is extraordinary, and will take a kings ransom for a large commercial organization to bring in.
The concept Frederic describes of not treating the result of...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.3¢ |
Change
0.003(0.81%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.8¢ | 30.3¢ | $535.5K | 1.723M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 68084 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 520465 | 20 |
View Market Depth
| Last trade - 11.55am 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
